(NASDAQ: FBRX) Forte Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Forte Biosciences's earnings in 2026 is -$51,742,000.On average, 8 Wall Street analysts forecast FBRX's earnings for 2026 to be -$49,928,605, with the lowest FBRX earnings forecast at -$59,540,522, and the highest FBRX earnings forecast at -$35,776,926. On average, 6 Wall Street analysts forecast FBRX's earnings for 2027 to be -$55,295,144, with the lowest FBRX earnings forecast at -$67,151,888, and the highest FBRX earnings forecast at -$29,989,482.
In 2028, FBRX is forecast to generate -$45,998,905 in earnings, with the lowest earnings forecast at -$63,100,677 and the highest earnings forecast at -$27,095,760.